Výsledky vyhledávání - "Autumn Olson"

Impact of baseline culture conditions of mouse-derived cancer organoids when determining therapeutic response and tumor heterogeneity

Autor: Rebecca A. DeStefanis, Dustin A. Deming, Alyssa K. DeZeeuw, Cheri A. Pasch, Gioia Sha, Autumn Olson, Katherine A. Johnson, Jeremy D. Kratz, Amani A. Gillette, Linda Clipson, Melissa C. Skala

Representative models are needed to screen new therapies for patients with cancer. Cancer organoids are a leap forward as a culture model that faithfully represents the disease. Mouse-derived cancer organoids (MDCOs) are becoming increasingly popular

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::49491851ff86f2b958985b5769bfb3f7
https://doi.org/10.1101/2021.10.12.464087

Zobrazit plný text záznamu

Abstract 2969: Impact of baseline culture condition on the growth and treatment response of mouse derived cancer organoids

Autor: Cheri A. Pasch, Autumn Olson, Linda Clipson, Gioia Sha, Rebecca A. DeStefanis, Samantha F. Anderson, Dustin A. Deming, Jeremy D. Kratz, Alyssa K. DeZeeuw

Publikováno v: Cancer Research. 81:2969-2969

Impact of baseline culture condition on the growth and treatment response of mouse derived cancer organoidsAuthors: Autumn Olson, Rebecca A. DeStefanis, Alyssa DeZeeuw, Samantha Anderson, Gioia Sha, Jeremy Kratz, Cheri Pasch, Linda Clipson, Dustin A.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::44ae78f84dea133609e5870150a1807a
https://doi.org/10.1158/1538-7445.am2021-2969

Zobrazit plný text záznamu

Abstract 1944: Navitoclax enhances the efficacy of copanlisib predominantly through inhibition of BCLxL in PIK3CA mutant colorectal cancer

Autor: Gioia Sha, Rebecca A. DeStefanis, Dustin A. Deming, Alyssa K. DeZeeuw, Christopher P. Babiarz, Linda Clipson, Cheri A. Pasch, Samantha J. Anderson, Autumn Olson

Publikováno v: Cancer Research. 81:1944-1944

Background: Mutations in PIK3CA occur in 18% of colorectal cancers (CRC) and result in constitutive activation of the PI3K pathway. Previous work from our lab has determined that MTORC1/2 inhibition, with copanlisib (cop), a PI3K/MTOR inhibitor, is s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c5759d8fa54bbdeec05666ab0eb7668c
https://doi.org/10.1158/1538-7445.am2021-1944

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání